BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28638981)

  • 1. Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis.
    Oshagbemi OA; Driessen JHM; Pieffers A; Wouters EFM; Geusens P; Vestergaard P; van den Bergh J; Franssen FME; de Vries F
    Osteoporos Int; 2017 Oct; 28(10):2859-2866. PubMed ID: 28638981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of high-dose intermittent systemic glucocorticoids and the risk of fracture in patients with chronic obstructive pulmonary disease.
    Oshagbemi OA; Burden AM; Shudofsky KN; Driessen JHM; Vestergaard P; Krings A; Franssen FME; van den Bergh J; de Vries F
    Bone; 2018 May; 110():238-243. PubMed ID: 29462672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort.
    Bours S; de Vries F; van den Bergh JPW; Lalmohamed A; van Staa TP; Leufkens HGM; Geusens PPP; Drent M; Harvey NC
    Osteoporos Int; 2016 Apr; 27(4):1603-1610. PubMed ID: 26630976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study.
    Amiche MA; Abtahi S; Driessen JHM; Vestergaard P; de Vries F; Cadarette SM; Burden AM
    Arch Osteoporos; 2018 Mar; 13(1):30. PubMed ID: 29552730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
    Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
    Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures.
    Egeberg A; Schwarz P; Harsløf T; Andersen YMF; Pottegård A; Hallas J; Thyssen JP
    JAMA Dermatol; 2021 Mar; 157(3):275-282. PubMed ID: 33471030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of fragility fracture among patients with sarcoidosis: a population-based study 1976-2013.
    Ungprasert P; Crowson CS; Matteson EL
    Osteoporos Int; 2017 Jun; 28(6):1875-1879. PubMed ID: 28210775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis.
    Safipour Z; van der Zanden R; van den Bergh J; Janssen P; Vestergaard P; de Vries F; Driessen JHM
    Osteoporos Int; 2022 Mar; 33(3):649-658. PubMed ID: 34601629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark.
    Vestergaard P; Olsen ML; Paaske Johnsen S; Rejnmark L; Sørensen HT; Mosekilde L
    J Intern Med; 2003 Nov; 254(5):486-93. PubMed ID: 14535971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
    Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
    Ann Rheum Dis; 2021 Apr; 80(4):423-431. PubMed ID: 33310727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal age of commencing and discontinuing thiazide therapy to protect against fractures.
    Kruse C; Eiken P; Vestergaard P
    Osteoporos Int; 2016 May; 27(5):1875-85. PubMed ID: 26659068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of fracture in incident multiple sclerosis patients: the Danish National Health Registers.
    Bazelier MT; Bentzen J; Vestergaard P; Stenager E; Leufkens HG; van Staa TP; de Vries F
    Mult Scler; 2012 Nov; 18(11):1609-16. PubMed ID: 22472998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fracture rate in patients with myasthenia gravis: the general practice research database.
    Pouwels S; de Boer A; Javaid MK; Hilton-Jones D; Verschuuren J; Cooper C; Leufkens HG; de Vries F
    Osteoporos Int; 2013 Feb; 24(2):467-76. PubMed ID: 22531999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures-the OPENTHYRO register cohort.
    Abrahamsen B; Jørgensen HL; Laulund AS; Nybo M; Brix TH; Hegedüs L
    J Bone Miner Res; 2014 Sep; 29(9):2040-50. PubMed ID: 24723381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions.
    Balasubramanian A; Wade SW; Adler RA; Saag K; Pannacciulli N; Curtis JR
    J Bone Miner Res; 2018 Oct; 33(10):1881-1888. PubMed ID: 29924418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom.
    Bultink IE; Harvey NC; Lalmohamed A; Cooper C; Lems WF; van Staa TP; de Vries F
    Osteoporos Int; 2014 Apr; 25(4):1275-83. PubMed ID: 24297094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink.
    Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
    Rheumatology (Oxford); 2022 Apr; 61(4):1448-1458. PubMed ID: 34255815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoids Increase Fracture Risk and Fracture Prevalence Independently from Bone Mineral Density and Clinical Risk Factors: Results from the Gliwice Osteoporosis (GO) Study.
    Pluskiewicz W; Adamczyk P; Drozdzowska B
    Horm Metab Res; 2022 Jan; 54(1):20-24. PubMed ID: 34986496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway.
    Apalset EM; Lunde A; Hoff M; Ehrenstein V; Tell GS
    Arch Osteoporos; 2020 Aug; 15(1):121. PubMed ID: 32757143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative hyperthyroid as opposed to hypothyroid time: an observational register-based time-resolved cohort analysis.
    Abrahamsen B; Jørgensen HL; Laulund AS; Nybo M; Bauer DC; Brix TH; Hegedüs L
    J Bone Miner Res; 2015 May; 30(5):898-905. PubMed ID: 25431028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.